Sign Out
Non-Small Cell Lung Cancer (NSCLC): IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥4 cm and/or node positive) NSCLC and no known EGFR mutation or ALK rearrangements.
IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitizing EGFR mutations or ALK positive mutations.
Small Cell Lung Cancer (SCLC): IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancer (BTC): IMFINZI in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).
Hepatocellular Carcinoma (HCC): IMFINZI in combination with tremelimumab is indicated for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
Endometrial Cancer: IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR); IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Continue with Google